Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 12:5:62.
doi: 10.3389/fmed.2018.00062. eCollection 2018.

Comorbidities in Spondyloarthritis

Anna Moltó  1   2 , Elena Nikiphorou  3   4
Affiliations
Review

Comorbidities in Spondyloarthritis

Anna Moltó et al. Front Med (Lausanne). .

Abstract

Comorbidities in spondyloarthritis (SpA) add to the burden of disease by contributing to disease activity, functional and work disability, and mortality. Thus, awareness of comorbidities in SpA is crucial to improve their screening and management and to ultimately improve outcomes in those affected. Osteoporosis has been reported to be the most prevalent comorbidity in SpA, and its risk is increased in these patients, compared with the general population; the risk of vertebral fractures requires further evaluation. Cardiovascular risk is also increased in this population, both due to an increase of the traditional cardiovascular risk factors in these patients, but also due to the presence of inflammation. The role of non-steroidal anti-inflammatory drugs in this increased risk needs further elucidation, but there is consensus on the need to encourage smoking cessation and to perform periodic evaluation of cardiovascular risk in these patients, particularly in the case of change in treatment course. Concerning the risk of cancer, no increased risk inherent to SpA seems to exist. However, an increased neoplastic risk can occur due to SpA treatments, e.g., P-UVA. Data are sparse on the risk of infections compared with rheumatoid arthritis, but there appears to be no risk in the absence of TNF-inhibitor exposure. Regardless of which comorbidity, a gap exists between recommendations for their management and actual implementation in clinical practice, suggesting that there is still a need for improvement in this area. Systematic screening for these comorbidities should improve both short- and long-term outcomes in SpA patients.

Keywords: cancer; cardiovascular; comorbidity; infection; osteoporosis; spondyloarthritis.

PubMed Disclaimer

References

    1. Dougados M, Baeten D. Spondyloarthritis. Lancet (2011) 377:2127–37.10.1016/S0140-6736(11)60071-8 - DOI - PubMed
    1. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis (1970) 23:455–68.10.1016/0021-9681(70)90054-8 - DOI - PubMed
    1. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med (2009) 7:357–63.10.1370/afm.983 - DOI - PMC - PubMed
    1. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol (2008) 26:S35–61. - PubMed
    1. Moltó A, Etcheto A, van der Heijde D, Landewé R, van den Bosch F, Bautista Molano W, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis (2016) 75:1016–23.10.1136/annrheumdis-2015-208174 - DOI - PubMed

LinkOut - more resources